Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates ...
A demonstrated 100% concordance between biomarker-guided predictions from pre-treatment patient samples and clinical outcomes ...
A novel mouse model of a highly lethal form of acute myeloid leukemia (AML) offers a new tool for scientists working to better understand this disease and research new therapeutic targets. Scientists ...
AUTX-703, a first-in-class oral KAT2A/B degrader, received FDA fast track designation for relapsed or refractory AML treatment. Promising preclinical data showed AUTX-703's effective KAT2A/B ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results